Logo image of TBI

TRUEBLUE INC (TBI) Stock Fundamental Analysis

NYSE:TBI - New York Stock Exchange, Inc. - US89785X1019 - Common Stock - Currency: USD

5.74  +0.08 (+1.41%)

After market: 5.74 0 (0%)

Fundamental Rating

3

TBI gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 82 industry peers in the Professional Services industry. TBI has a great financial health rating, but its profitability evaluates not so good. TBI has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year TBI has reported negative net income.
In the past year TBI has reported a negative cash flow from operations.
In multiple years TBI reported negative net income over the last 5 years.
Of the past 5 years TBI 4 years had a positive operating cash flow.
TBI Yearly Net Income VS EBIT VS OCF VS FCFTBI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

1.2 Ratios

TBI has a Return On Assets of -18.62%. This is amonst the worse of the industry: TBI underperforms 81.71% of its industry peers.
TBI's Return On Equity of -39.87% is on the low side compared to the rest of the industry. TBI is outperformed by 80.49% of its industry peers.
Industry RankSector Rank
ROA -18.62%
ROE -39.87%
ROIC N/A
ROA(3y)-4.7%
ROA(5y)-4.52%
ROE(3y)-10.14%
ROE(5y)-10.07%
ROIC(3y)N/A
ROIC(5y)N/A
TBI Yearly ROA, ROE, ROICTBI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20 -30

1.3 Margins

TBI has a worse Gross Margin (25.93%) than 67.07% of its industry peers.
In the last couple of years the Gross Margin of TBI has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for TBI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 25.93%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.19%
GM growth 5Y-0.39%
TBI Yearly Profit, Operating, Gross MarginsTBI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20

More info and screens

7

2. Health

2.1 Basic Checks

TBI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TBI has been reduced compared to 1 year ago.
The number of shares outstanding for TBI has been reduced compared to 5 years ago.
Compared to 1 year ago, TBI has a worse debt to assets ratio.
TBI Yearly Shares OutstandingTBI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
TBI Yearly Total Debt VS Total AssetsTBI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

An Altman-Z score of 3.32 indicates that TBI is not in any danger for bankruptcy at the moment.
TBI has a Altman-Z score of 3.32. This is in the better half of the industry: TBI outperforms 62.20% of its industry peers.
TBI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.32
ROIC/WACCN/A
WACC9.45%
TBI Yearly LT Debt VS Equity VS FCFTBI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

TBI has a Current Ratio of 1.73. This is a normal value and indicates that TBI is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of TBI (1.73) is better than 69.51% of its industry peers.
A Quick Ratio of 1.73 indicates that TBI should not have too much problems paying its short term obligations.
With a decent Quick ratio value of 1.73, TBI is doing good in the industry, outperforming 69.51% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.73
Quick Ratio 1.73
TBI Yearly Current Assets VS Current LiabilitesTBI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

3

3. Growth

3.1 Past

TBI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -300.00%.
Looking at the last year, TBI shows a very negative growth in Revenue. The Revenue has decreased by -17.78% in the last year.
The Revenue has been decreasing by -7.93% on average over the past years.
EPS 1Y (TTM)-300%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1433.33%
Revenue 1Y (TTM)-17.78%
Revenue growth 3Y-10.33%
Revenue growth 5Y-7.93%
Sales Q2Q%-8.09%

3.2 Future

TBI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 71.71% yearly.
Based on estimates for the next years, TBI will show a small growth in Revenue. The Revenue will grow by 3.33% on average per year.
EPS Next Y22.57%
EPS Next 2Y71.71%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-0.13%
Revenue Next 2Y3.33%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
TBI Yearly Revenue VS EstimatesTBI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 500M 1B 1.5B 2B 2.5B
TBI Yearly EPS VS EstimatesTBI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 1 2

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TBI. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 13.45, the valuation of TBI can be described as correct.
73.17% of the companies in the same industry are more expensive than TBI, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 21.76. TBI is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 13.45
TBI Price Earnings VS Forward Price EarningsTBI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TBI Per share dataTBI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30 40 50

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
TBI's earnings are expected to grow with 71.71% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y71.71%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TBI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TRUEBLUE INC

NYSE:TBI (5/23/2025, 8:58:15 PM)

After market: 5.74 0 (0%)

5.74

+0.08 (+1.41%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCommercial & Professional Services
GICS IndustryProfessional Services
Earnings (Last)05-05 2025-05-05/amc
Earnings (Next)08-04 2025-08-04/amc
Inst Owners99.85%
Inst Owner Change-0.75%
Ins Owners3.29%
Ins Owner Change18.94%
Market Cap171.11M
Analysts80
Price Target8.16 (42.16%)
Short Float %3.12%
Short Ratio3.24
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)58.77%
Min EPS beat(2)29.73%
Max EPS beat(2)87.81%
EPS beat(4)3
Avg EPS beat(4)-100.99%
Min EPS beat(4)-629.55%
Max EPS beat(4)108.03%
EPS beat(8)5
Avg EPS beat(8)34.54%
EPS beat(12)8
Avg EPS beat(12)30.12%
EPS beat(16)11
Avg EPS beat(16)58.98%
Revenue beat(2)0
Avg Revenue beat(2)-1.34%
Min Revenue beat(2)-1.94%
Max Revenue beat(2)-0.75%
Revenue beat(4)0
Avg Revenue beat(4)-2.1%
Min Revenue beat(4)-5.35%
Max Revenue beat(4)-0.38%
Revenue beat(8)1
Avg Revenue beat(8)-1.94%
Revenue beat(12)2
Avg Revenue beat(12)-1.58%
Revenue beat(16)6
Avg Revenue beat(16)-0.76%
PT rev (1m)-25%
PT rev (3m)-31.43%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-76.39%
EPS NY rev (1m)1.43%
EPS NY rev (3m)-220.93%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.89%
Revenue NY rev (1m)1.87%
Revenue NY rev (3m)0.7%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 13.45
P/S 0.11
P/FCF N/A
P/OCF N/A
P/B 0.54
P/tB 0.6
EV/EBITDA N/A
EPS(TTM)-0.88
EYN/A
EPS(NY)0.43
Fwd EY7.43%
FCF(TTM)-1.38
FCFYN/A
OCF(TTM)-0.57
OCFYN/A
SpS52.58
BVpS10.58
TBVpS9.56
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -18.62%
ROE -39.87%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 25.93%
FCFM N/A
ROA(3y)-4.7%
ROA(5y)-4.52%
ROE(3y)-10.14%
ROE(5y)-10.07%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.19%
GM growth 5Y-0.39%
F-Score4
Asset Turnover2.32
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 81.7%
Cap/Sales 1.54%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.73
Quick Ratio 1.73
Altman-Z 3.32
F-Score4
WACC9.45%
ROIC/WACCN/A
Cap/Depr(3y)102.48%
Cap/Depr(5y)103.83%
Cap/Sales(3y)1.51%
Cap/Sales(5y)1.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-300%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1433.33%
EPS Next Y22.57%
EPS Next 2Y71.71%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-17.78%
Revenue growth 3Y-10.33%
Revenue growth 5Y-7.93%
Sales Q2Q%-8.09%
Revenue Next Year-0.13%
Revenue Next 2Y3.33%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-209.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year115.68%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-1396.7%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-149.51%
OCF growth 3YN/A
OCF growth 5YN/A